All News

Feb
15
2024

AcouSort presents at RedEye Regenerative medicine/ Cell Therapy event

AcouSort’s CEO Torsten Freltoft presents at RedEye Regenerative medicine/ Cell Therapy event in Stockholm February 14 2024. Follow the link to read more and access the presentation: Here

Read More
Jan
31
2024

Significant technical progress in the AcouSome project – two novel patent applications filed

In August 2022, the European Innovation Council (EIC) awarded the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology enabling exosome-based diagnostics. The aim of the project is to

Read More
Jan
18
2024

AcouSort extends collaboration with leading cell therapy company into a third project phase

AcouSort’s collaboration with the global life science company has reached yet another significant milestone with the signing of a Statement of Work (SoW) describing Phase 3 in the ongoing collaboration.

Read More
Jan
16
2024

AcouSort attends Advanced Therapies Week to extend its cell therapy network

The Phacilitate Network consists of over 1,800 industry experts within cell and gene therapy. For 20 years, the network has hosted the Advanced Therapies Week for knowledge sharing, relationship building

Read More
Dec
19
2023

The board of directors resolves to repurchase warrants series 2020/2023

The board of directors of AcouSort AB, 556824-1037 (“AcouSort”, the “Company”) decided on December 18, 2023, that the Company resolves to repurchase Warrants of series 2020/2023 as set out below:

Read More
Dec
12
2023

AcouSort’s rights issue is registered – conversion of BTU into shares and warrants

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND,

Read More
Dec
11
2023

FDA approval paves the way for AcouSort’s first OEM commercialization within critical care diagnostics

AcouSort AB (publ) (“AcouSort”, the “Company”) today announces that the Company and its partner within critical care diagnostics have updated their collaboration agreement. The updated agreement follows the FDA approval

Read More
Dec
4
2023

AcouSort’s rights issue fully subscribed

AcouSort AB (publ) (“AcouSort” or the “Company”) announces today the final outcome of the rights issue of units with pre-emption rights for the Company’s shareholders, consisting of shares and series

Read More
Nov
30
2023

AcouSort announces preliminary outcome of rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND,

Read More
Nov
30
2023

AcouSort changes Certified Adviser to Carnegie Investment Bank AB (publ)

AcouSort has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on

Read More